on the HUNT for the Next DIAMOND in the ROUGH
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
$AMBS for all those new here ....I would watch the videos to better understand the Co. and their future plans concerning partners and how many they can have with MANF
Just because they partner with a co. for Manf for treatment of Parkinson.....they can also partner same Manf for Heart Disease, Diabetes....Etc.
This Protein is a Medical breakthrough and all the Big Biotechs will want a Piece of It
My head is still spinning....... this may hit .05 tomorrow!
Market Cap. still low for all the patents that they own
last call.....may be more significant news in AM
AMBS bought By AMGEN Co-Founder(LARGEST Indep. BIOTECH)
Amgen is the world's largest independent biotechnology firm. Epogen and Neupogen (the company's first products on the market) were the two most successful biopharmaceutical products at the time of their respective releases.
still at looow levels
This is going to be the play of the year!
.03 by EOD tomorrow
we all know what happened with that PPS. but this is even Better
This will be the next Co. on 60 Minutes
When they went public last year it was @ .50
The best part is there should be no side effects
Is everyone aware yet of the discovery this Co. has made and the limitless possibilities?
Other Big Biotech have spent over 400 million to develop GDNF
Amarantus BioSciences Announces MANF Demonstrates Superiority over GDNF in Neurorestoration Behavioural Animal Model of Parki...
Amarantus Biosci (OTCBB:AMBS)
Historical Stock Chart
1 Month : From Sep 2012 to Oct 2012
Click Here for more Amarantus Biosci Charts.
SUNNYVALE, Calif., Oct. 25, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centred on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has received positive behavioural efficacy data for MANF in a neurorestoration 6-hydroxydopamine (6-OHDA) rat model of Parkinson's disease. The data shows superiority of MANF over GDNF, a neurotrophic factor currently in a Phase 2 clinical trial as a disease-modifying treatment for Parkinson's disease, by demonstrating that when MANF is delivered directly to the primary brain region associated with Parkinson's called the substantia nigra, MANF significantly reduced behavioural deficits in the model, whereas GDNF did not.
In Parkinson's disease, the nigro-striatal network (substantia nigra – striatum) is compromised due to the degeneration of dopaminergic neurons in the substantia nigra, which results in dopaminergic nerve terminal retraction from the striatum towards the substantia nigra. This leaves the striatum with inadequate dopamine levels, which in turn causes motor function deficits and other symptoms. Currently approved drugs that relieve symptoms focus on replacing the dopamine lost in the striatum; however, the symptom relief is temporary and the drugs typically lose their ability to abate symptoms roughly 7-10 years after the initiation of drug therapy. There are no approved therapies that focus on re-innervating the striatum by protecting dopaminergic neuron cell bodies in the substantia nigra while restoring dopaminergic innervation in the striatum.
In rat studies conducted by an independent academic laboratory contracted by Amarantus, 6-OHDA was injected directly into the striatum on one side of each rat's brain, causing their dopaminergic terminals to retract from the striatum towards the substantia nigra, and creating Parkinson's-like behavioural symptoms that were quantified by counting the number of times the rats turned in a circle in the same direction (behavioural deficits) in a given 120 minute period of time. MANF and GDNF were delivered directly into the substantia nigra of separate groups of rats 2 weeks following the administration of the 6-OHDA, in order to mimic as closely as possible in rats the treatment setting in humans where treatment would be administered after an extended timeframe following the initiation of dopaminergic nerve terminal retraction, each at the optimal dosing level of 10 micrograms. Four weeks following MANF treatment into the substantia nigra, behavioural deficits were reduced by ~43%, and six weeks following MANF treatment, behavioural deficits were reduced by ~53%; four weeks following GDNF treatment into the substantia nigra, behavioural deficits were reduced by ~16%, and six weeks following GDNF treatment, behavioural deficits actually increased by ~20%.
"The data obtained in this study provide clear evidence that MANF had a strong positive and restorative effect on the behaviour of animals in this pre-clinical Parkinson's disease study when delivered to the substantia nigra, whereas GDNF had no such effect," said John W. Commissiong PhD, Chief Scientist at Amarantus and former Head of the Neurotrophic Factors Group at the National Institutes of Health. "The localization of the drug treatment in this study is critical because, as Parkinson's disease progresses, dopaminergic nerve terminals typically retract from the striatum towards their cell bodies in the substantia nigra, resulting in the disruption of the basal ganglia network that is responsible for proper motor function. Translated, the longer you have Parkinson's disease, the less likely a neurotrophic factor will work when delivered to the striatum because there are fewer dopaminergic nerve terminals remaining to act on, and so neurotrophic factor drugs for later-stage patients will likely work best when delivered to the substantia nigra. No neurotrophic factor other than MANF has demonstrated efficacy in the neurorestoration behavioural 6-OHDA model of Parkinson's disease when delivered to the substantia nigra, so this makes today's result very significant. We are currently working to complete the analysis of histology data to confirm that it is in fact dopaminergic re-innervation of the striatum that is responsible for the results reported today. We expect to release the final results, including histology, to the public when the final data package is assembled in the next few months, and we will submit the final study report and manuscript for publication to a peer-reviewed scientific journal jointly with our academic collaborators and study sponsors at the same time. If the histology data confirm the mechanism underlying the behavioural results reported today, the biology causing today's result would represent a major scientific achievement that could lead to a medical breakthrough in treating Parkinson's disease."
Neurotrophic factors have been promising drug candidates for Parkinson's disease for over two decades because they have special biological properties that allow them to selectively protect certain neurons. Large biotechnology companies and leading academic investigators have conducted a number of clinical trials on GDNF in Parkinson's disease first initiated in 1996, at an estimated total cost of over $400M, where GDNF has shown promise as a disease-modifying treatment. However, technological limitations of delivering neurotrophic factors to the brain, limitations that Amarantus believes have been resolved by researchers in academia and industry, have delayed the translation of the underlying biology of neurotrophic factors into approved medicines. A unique drug such as MANF that potentially acts by re-innervating the striatum when delivered to the substantia nigra, combined with newly improved delivery technologies capable of getting MANF to the substantia nigra, could complement or replace drugs in development that may get to market ahead of MANF, especially in later-stage patients.
"Today's announcement is transformational for Amarantus from a scientific data standpoint," said Gerald E. Commissiong, President & CEO of Amarantus. "Despite the many clear scientific advantages we believe MANF possesses over GDNF, most notably impacting protein folding and modulating toxic calcium levels, the Company had previously been unable to point to a definitive behavioural animal model data to show improved benefit of MANF over GDNF in the Parkinson's disease indication. The data we now have validates the approach we have been taking over the last several years, and we believe that it will allow us to attract the interest of investment firms and potential partners who will be able to now characterize the substantial opportunity our technology represents. We believe that we are well positioned to leverage the MANF opportunity for Amarantus shareholders and Parkinson's patients because of the expansive intellectual property (IP) portfolio the Company owns, including composition of matter patents in the US and Europe, use patents worldwide and provisional delivery dosing patents that have been filed based on today's data, extending marketing exclusivity for MANF through 2031. This IP position may make MANF more attractive to a potential partner than other neurotrophic factors in development that do not have the same patent runway."
About Amarantus BioSciences, Inc.
Amarantus BioSciences, Inc. is a development-stage biotechnology company founded in January 2008. The Company has a focus on developing certain biologics surrounding the intellectual property and proprietary technologies it owns to treat and/or diagnose Parkinson's disease, Traumatic Brain Injury and other human diseases. The Company owns the intellectual property rights to a therapeutic protein known as Mesencephalic-Astrocyte-derived Neurotrophic Factor ("MANF") and is developing MANF-based products as treatments for brain disorders. The Company also is a Founding Member of the Coalition for Concussion Treatment (#C4CT), a movement initiated in collaboration with Brewer Sports International seeking to raise awareness of new treatments in development for concussions and nervous-system disorders. For further information please visit www.Amarantus.com.
Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about the possible benefits of MANF therapeutic applications and/or advantages presented by Amarantus' PhenoGuard technology, as well as statements about expectations, plans and prospects of the development of Amarantus' new product candidates. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risks that the anticipated benefits of the therapeutic drug candidates or discovery platforms, as well as the risks, uncertainties and assumptions relating to the development of Amarantus' new product candidates, including those identified under "Risk Factors" in Amarantus' most recently filed Annual Report on Form 10-K and Quarterly Report on Form 10-Q and in other filings Amarantus periodically makes with the SEC. Actual results may differ materially from those contemplated by these forward-looking statements Amarantus does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this presentation.
MEDIA CONTACTS
Amarantus BioSciences, Inc.
Gerald E. Commissiong
408-737-2734
pr@amarantus.com
SOURCE Amarantus BioSciences, Inc.
Copyright 2012 PR Newswire
Myocardial infarction (MI) or acute myocardial infarction (AMI), commonly known as a heart attack
Amarantus BioSciences Provides Update to Shareholders
SUNNYVALE, Calif. – October 10, 2012
As new and exciting proof-of-concept data for MANF in secondary therapeutic indications continues to be published by research laboratories throughout Europe, China, Japan and North America, the value of our intellectual property (“IP”) portfolio is steadily increasing. We are continually expanding our IP portfolio for MANF by filing and aggregating new patents
this is the Co. that got 20 million from the Department of Defense
Amarantus BioSciences, Inc. (OTCBB: AMBS), a biotechnology company developing new treatments for brain-related disorders including traumatic brain injury (TBI) based on its proprietary anti-apoptotic therapeutic protein known as MANF and Banyan Biomarkers, the leader in developing in vitro diagnostic products to detect TBI, today announced the successful completion of a collaboration agreement initiated in November 2011 to evaluate MANF’s potential as a disease-modifying agent for the treatment of TBI.
for those that don't know Bristol Myers has a 55 BILLION $ market CAP.
I think he has all the tools and contacts to bring us to the next level
Amarantus BioSciences Appoints Clinton O. Allen To Advisory Board
SUNNYVALE, Calif. – October 19, 2012 – Amarantus BioSciences, Inc. (OTCQB: AMBS), a biotechnology company developing new treatments and diagnostics for Parkinson’s disease and Traumatic Brain Injury centred on its proprietary anti-apoptotis therapeutic protein MANF, today announced that it has appointed Clinton O. Allen to its Advisory Board. Mr. Allen will work with management at Amarantus to improve internal controls, prepare due diligence materials for investors and implement corporate governance best practices.
“Clinton Allen is a seasoned biopharmaceutical executive with exceptional leadership capabilities and experience in Big Pharma,” said Gerald E. Commissiong, President & CEO of Amarantus. “He will be a tremendous asset for the Company as we execute on our corporate strategy
Mr. Allen has extensive experience in the biopharmaceutical space. He has held senior leadership positions at Bristol Myers Squibb as Senior Director of Corporate Compliance Audit, Director of Risk Management, Director of Product Development and Commercialization, Director of In-licensing and Business Development. Mr. Allen was a captain in the United States Army and received his master in in Environmental Management & Sciences from Tufts University.
“I am very excited to join Amarantus at this critical time in its growth cycle,” said Clinton O. Allen, newly appointed advisor to Amarantus. “The team at Amarantus has been working tremendously hard over the last few years to bring the MANF Program closer to actualizing its true potential. Now that the Company is looking at various partnering and funding opportunities to drive shareholder value, it is an opportune time to join the team in order to meticulously evaluate proposals and make recommendations for future growth. About Amarantus
Rationale to follow Amarantus: Currently, available treatments for degenerative neurological disorders
such as Parkinson’s disease only alleviate patient symptoms, and do not function to reverse or stop disease
progression. Therefore, there is a critical need for curative therapies that can impede the deterioration of the
nervous system, which is the root cause of these neurological conditions. Amarantus BioSciences [OTC BB:
AMBS] is pioneering the development of a novel therapeutic protein that has neuron-protective properties –
termed MANF – which has the potential to serve as a first-in-class treatment for neurological disorders that
stops and/or reverses their debilitating effects. Importantly, MANF is also significantly cardiac-protective,
providing Amarantus the ability to employ a two pronged drug development approach – a neurological
disorder platform, and a heart disease platform.
Amarantus’ license for NuroPro, our clinical-stage Parkinson’s disease diagnostic blood test, has several potential positive benefits for our MANF Parkinson’s program including the identification of patients most likely to respond to MANF treatment. We intend to immediately
pursue a partnering strategy for NuroPro and expect to update the marketplace once definitive agreements are reached. NuroPro could become a significant source of revenue for the Company within a relatively short period of time and its further development could have a major impact on the way Parkinson’s disease is diagnosed and managed by physicians.
In closing, the team at Amarantus has been working tirelessly to complete the goals we put out
Since 2011, the Company has reported positive data in pre-clinical models of Parkinson’s disease, Traumatic Brain Injury and Myocardial. The Company owns composition of matter and method of use patents and patent applications for MANF worldwide. Amarantus is focused primarily on the development of a MANF-based treatment for Parkinson’s disease
The Department of Defense has already funded one of their partners 20 million for TBI (tramatic Brain Injury
HEART DISEASE positive research data
http://ih.advfn.com/p.php?pid=nmona&article=54308207
CELL DEATH IS THE CAUSE OF MANY DISEASES Parkinson's is just the start
MANF can stop the cell death of neurons, therefore arresting the progression of Parkinson’s disease in pre-clinical
studies. Building on the finding that broad MANF production in the body is important for stabilization of the nervous system,
studies have been performed to determine if MANF can stop neuron death in animal models of Parkinson’s disease
MANF is up-regulated in the adaptive pathway of the Unfolded Protein Response, resulting in the prevention
of apoptosis. MANF selectively protects nigral dopaminergic neurons, and is more selective in the protection
of dopaminergic neurons at lower and middle concentrations than glial cell line-derived neurotrophic factor
and brain-derived neurotrophic factor. In the brain, relatively high MANF levels were detected in the cerebralcortex, hippocampus and cerebellar Purkinje cells. APOPTOSIS is CELL DEATH
Animal and human studies confirm that MANF is a
biological protein that is produced in the body to establish and maintain the nervous system. Furthermore,
studies have shown that MANF is also highly produced during times of cardiac stress, indicating that this
protein plays a crucial role in heart health.
MANF (AMRS001) was discovered studying Amarantus’ first established cell line of neurons. It was found to
have a striking ability to save neurons from cell death when disease conditions were presented. This was a
remarkable finding in regard to therapeutic potential, as neuron cell death is the underlying cause of
neurologic conditions such as Parkinson’s disease.
Amarantus has developed over 80 PhenoGaurd cell lines to date, and has utilized their PhenoGaurd Protein
Discovery Engine to identify MANF as a potential breakthrough therapy for neurological disorders and
cardiac disease.
Background: Amarantus has actualized two leading-edge technologies that enable the discovery of
therapeutic proteins with the potential to treat high-need medical conditions: the PhenoGuard Cell Line
Library; and the PhenoGaurd Protein Discovery Engine. The PhenoGaurd Cell Line Library is the company’s
proprietary stock of different mammalian cell types that maintain the properties of the original tissue from
which they were derived. These cell lines are not genetically engineered in any way and can be maintained
indefinitely in the lab, providing Amarantus with an invaluable biological substratum to study the normal and
disease states of the body.The company’s PhenoGaurd Protein Discovery Engine applies disease-specific
stress conditions to their cell lines, and then studies different therapeutic candidates that save the cells from
damage.
Market opportunity: Over 1.5 million people suffer from Parkinson’s disease in the United States, Western
Europe, and Japan alone. The NIH estimates at least 500,000 people in the United States suffer from PD,
and the total cost to the nation exceeds $6B annually. The company has stated the incidence of PD is likely
to double in the next 20 years due to increase in average lifespan, coupled with a larger population
approaching retirement. In 2009, the PD market generated $2.2B across the seven major markets. Between
2005 and 2009, the dopamine agonist class dominated the market, accounting for nearly half of PD market
sales. Additionally, newer catechol-O-methyltransferase inhibitor and monoamine oxidase inhibitor classes
have continued to penetrate the market. It is predicted that generic incursion in these classes will limit the
market share, and a continued unimpressive late-stage pipeline with unproven benefits and differentiation
will open the door for a new first-in-class opportunity.
From ONE MED PLACE
The stock has significant upside – it is trading below a penny, as the company recently reached the end of
the ‘lock-up period’ following a reverse merger in July 2011, which diluted shareholder equity. The company
effectively experienced a toxic convert death-spiral – which led to a flooding of shares driving the stock price
down even further. These factors have driven the stock price down 96% YTD. However, the company’s
diverse and robust pipeline opens the door for a series of significant catalysts in the second half of 2012. In
January 2012, Amarantus was awarded a US patent on MANF, and this year announced it would begin
developmental timelines for the product. If the technology works (and pre-clinical data suggests this is the
case), we should expect the stock to soar following these milestones and the bottoming out post-lock-up
period. Further, the company believes it can be successful in financing efforts, which can bring MANF to
clinical phase sooner rather than later. As of September 21, 2012, the stock trades at a volume of 827,000.
Sorry If everyone already knows about whats going on with this Co.- I'm just trying to make it easier for those new to jump on before this skyrockets
Amarantus BioSciences Retains JS Barkats in New York as Corporate & Securities Counsel
Date : 10/15/2012 @ 8:17AM
Source : PR Newswire
Stock : Amarantus Biosci (AMBS)
Quote : 0.0062 0.0 (0.00%) @ 5:32AM
Amarantus BioSciences Retains JS Barkats in New York as Corporate & Securities Counsel
Amarantus BioSciences, Inc. (OTCQB: AMBS), today announced that it has retained the legal services of JS Barkats, PLLC ("JS Barkats") to represent the Company as its corporate and securities counsel. Going forward, JSBarkats will represent the Company on all corporate, securities, capital markets, divestitures, partnerships, sponsorships and regulatory compliance matters. Amarantus will continue to work with Wilson, Sonsini, Goodrich & Rosati, LLP for all MANF intellectual property matters, and with Foley & Lardner, LLP on all diagnostic intellectual property matters.
"We are excited to represent Amarantus and be given the opportunity to bring value-added services to the table for our new client. Our team of experienced attorneys is impressed with the Company's proprietary technology and approach to treating Parkinson's disease and Traumatic Brain Injury," said Sunny Joseph Barkats, Founding Partner at JS Barkats. "Amarantus' corporate awareness programs, through its #C4CT concussion program and emerging relationships with professional athletes, are pioneering within development-stage biotechnology that will allow the Company to carve out a unique position for itself in the marketplace as it executes on its business strategy."
Robert Rash, the co-managing partner of the Firm in the Alabama offices added "As a CPA and a securities attorney, I am very interested in Amarantus revenue model being prosecuted through the aggregation and partnering of the Parkinson's NuroPro blood test and Alzheimer's LymPro blood test. JSBarkats believes this Company has extremely bright, talented people on its management team and the business approach is unique and innovative. Hence, we are delighted to represent Amarantus in order to assist management in maximizing the Company's value for shareholders."
About JSBarkats, PLLC:
JS Barkats, a boutique law firm headquartered in the heart of midtown-Manhattan in New York, has an experienced team of 22 attorneys with satellite offices in Alabama, Florida and Israel, as well as international affiliated offices. The firm specializes in, IPO's, APO's for public companies, SEC compliance and representation, intellectual property, licensing, corporate partnerships, tax law, commercial and securities litigation, entertainment and brand awareness. www.JSBarkats.com
Parkinsons is just the tip of the iceberg MANF has been shown to help with many other neurogical disorders as well. The key is the test to find early detection of these killers. Amarantus already has one for parkinsons and now onto Alzheimer's. With just these two alone...the market is HUGE If you do a little DD on MANF you will be amazed.
I feel grateful to be an investor in this Breakthrough Technology and Amarantus owns U.S and European to this compound which repairs cells that are dying when you have these conditions
A director should consider owning shares of the Company’s common stock having a dollar value of at least five times the value of the then-applicable annual retainer paid for service on the Board. Ownership is measured annually as of December 31 of each calendar year, based on the average closing price of a share of Amarantus stock as traded on the New York Stock Exchange for the last 30 trading days of the year.
http://www.amarantus.com/wp-content/uploads/2012/10/Amarantus-Biosciences-Corporate-Governance-Guidelines.pdf
10,500 followers of Company on twitter
https://twitter.com/AmarantusBio
once this starts heading North....we may very well see that gap filled quick
SUNNYVALE, Calif., Sept. 24, 2012 /PRNewswire/ -- Amarantus BioSciences, Inc. (OTCBB: AMBS), a California-based development-stage biotechnology developing new treatments and diagnostics for Parkinson's disease (PD) centered around its patented therapeutic protein MANF, today announced the release of a 2-page research report by OneMedPlace Research. The report can be found at http://www.onemedplace.com/reports/Amarantus_Research_Analysis.pdf.
Amarantus giving Fox, other Parkinsons sufferers new hope
SUNNYVALE, CA – When NBC made a 22-show series commitment in August to actor Michael J. Fox for a series to begin airing in 2013, it was an indication of the new hope for treatment of the Parkinson's disease which forced him from regular series television a dozen years ago.
Dr. John Commissiong presents scientific findings on MANF
Dr. John Commissiong presents scientific findings on MANF
Among the 50 Most Important African-Americans in Technology
One of the big reasons for that hope is a father-son team that created Amarantus BioSciences four years ago
http://www.blackmoney.com/35117
try to get in on the dip people
$AMBS Mesencephalic astrocyte-derived neurotrophic factor (MANF) protects the heart from Ischemic damage and is selectively secreted upon ER calcium depletion
http://www.jbc.org/content/early/2012/05/29/jbc.M112.356345
Maybe 2.00 by end of next year though